nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—MAPK14—hematologic cancer	0.153	0.664	CbGaD
Celecoxib—CA9—hematologic cancer	0.062	0.269	CbGaD
Celecoxib—colon cancer—Dexamethasone—hematologic cancer	0.0571	0.209	CpDpCtD
Celecoxib—colon cancer—Betamethasone—hematologic cancer	0.0571	0.209	CpDpCtD
Celecoxib—kidney cancer—Dexamethasone—hematologic cancer	0.0413	0.151	CpDpCtD
Celecoxib—kidney cancer—Betamethasone—hematologic cancer	0.0413	0.151	CpDpCtD
Celecoxib—MAPK14—Nilotinib—hematologic cancer	0.0356	0.121	CbGbCtD
Celecoxib—MAPK14—Dasatinib—hematologic cancer	0.0315	0.107	CbGbCtD
Celecoxib—prostate cancer—Betamethasone—hematologic cancer	0.0298	0.109	CpDpCtD
Celecoxib—prostate cancer—Dexamethasone—hematologic cancer	0.0298	0.109	CpDpCtD
Celecoxib—ABCC4—Tioguanine—hematologic cancer	0.0168	0.0573	CbGbCtD
Celecoxib—osteoarthritis—Prednisone—hematologic cancer	0.0168	0.0615	CpDpCtD
Celecoxib—ALB—hematologic cancer	0.0156	0.0676	CbGaD
Celecoxib—CA14—Imatinib—hematologic cancer	0.0136	0.0464	CbGbCtD
Celecoxib—CA6—Imatinib—hematologic cancer	0.0129	0.044	CbGbCtD
Celecoxib—CA14—Nilotinib—hematologic cancer	0.0124	0.0421	CbGbCtD
Celecoxib—CA6—Nilotinib—hematologic cancer	0.0118	0.04	CbGbCtD
Celecoxib—CA9—Imatinib—hematologic cancer	0.00967	0.0329	CbGbCtD
Celecoxib—CA12—Imatinib—hematologic cancer	0.00967	0.0329	CbGbCtD
Celecoxib—PTGS2—Lenalidomide—hematologic cancer	0.00905	0.0308	CbGbCtD
Celecoxib—CA9—Nilotinib—hematologic cancer	0.00879	0.0299	CbGbCtD
Celecoxib—CA12—Nilotinib—hematologic cancer	0.00879	0.0299	CbGbCtD
Celecoxib—CA2—Imatinib—hematologic cancer	0.00782	0.0266	CbGbCtD
Celecoxib—CA4—Nilotinib—hematologic cancer	0.00773	0.0263	CbGbCtD
Celecoxib—CA2—Nilotinib—hematologic cancer	0.00711	0.0242	CbGbCtD
Celecoxib—ABCC4—Mercaptopurine—hematologic cancer	0.00699	0.0238	CbGbCtD
Celecoxib—ORM1—Imatinib—hematologic cancer	0.00609	0.0207	CbGbCtD
Celecoxib—PTGS2—Thalidomide—hematologic cancer	0.00483	0.0165	CbGbCtD
Celecoxib—PTGS2—Triamcinolone—hematologic cancer	0.00335	0.0114	CbGbCtD
Celecoxib—CYP2C9—Bexarotene—hematologic cancer	0.00308	0.0105	CbGbCtD
Celecoxib—PTGS2—Betamethasone—hematologic cancer	0.00287	0.00979	CbGbCtD
Celecoxib—CYP2D6—Lomustine—hematologic cancer	0.00261	0.00891	CbGbCtD
Celecoxib—ALB—Imatinib—hematologic cancer	0.00256	0.00873	CbGbCtD
Celecoxib—CYP2C9—Idarubicin—hematologic cancer	0.00255	0.00868	CbGbCtD
Celecoxib—CYP2D6—Idarubicin—hematologic cancer	0.00233	0.00794	CbGbCtD
Celecoxib—ABCC4—Methotrexate—hematologic cancer	0.00229	0.00778	CbGbCtD
Celecoxib—PTGS2—Cisplatin—hematologic cancer	0.00207	0.00705	CbGbCtD
Celecoxib—PTGS2—Etoposide—hematologic cancer	0.00203	0.00692	CbGbCtD
Celecoxib—CYP2D6—Hydroxyurea—hematologic cancer	0.00198	0.00675	CbGbCtD
Celecoxib—CYP2C9—Bortezomib—hematologic cancer	0.00189	0.00642	CbGbCtD
Celecoxib—PTGS2—ovarian follicle—hematologic cancer	0.00181	0.0883	CbGeAlD
Celecoxib—CYP3A4—Bexarotene—hematologic cancer	0.00179	0.00609	CbGbCtD
Celecoxib—CYP2D6—Bortezomib—hematologic cancer	0.00172	0.00587	CbGbCtD
Celecoxib—ALB—Prednisone—hematologic cancer	0.00169	0.00575	CbGbCtD
Celecoxib—PTGS2—Dexamethasone—hematologic cancer	0.00167	0.00569	CbGbCtD
Celecoxib—CYP3A4—Lomustine—hematologic cancer	0.00166	0.00566	CbGbCtD
Celecoxib—CYP3A4—Busulfan—hematologic cancer	0.00166	0.00566	CbGbCtD
Celecoxib—CYP2C9—Thalidomide—hematologic cancer	0.00164	0.00559	CbGbCtD
Celecoxib—ALB—Irinotecan—hematologic cancer	0.0016	0.00545	CbGbCtD
Celecoxib—CYP2C9—Teniposide—hematologic cancer	0.00157	0.00534	CbGbCtD
Celecoxib—CYP3A4—Thiotepa—hematologic cancer	0.00148	0.00505	CbGbCtD
Celecoxib—CYP2C9—Ifosfamide—hematologic cancer	0.00145	0.00492	CbGbCtD
Celecoxib—PDPK1—hematopoietic system—hematologic cancer	0.00142	0.0693	CbGeAlD
Celecoxib—CYP2C9—Imatinib—hematologic cancer	0.00138	0.0047	CbGbCtD
Celecoxib—Etoricoxib—MAPK14—hematologic cancer	0.00138	1	CrCbGaD
Celecoxib—CYP2D6—Imatinib—hematologic cancer	0.00126	0.0043	CbGbCtD
Celecoxib—CYP2C9—Nilotinib—hematologic cancer	0.00126	0.00427	CbGbCtD
Celecoxib—CYP3A4—Methoxsalen—hematologic cancer	0.00115	0.00393	CbGbCtD
Celecoxib—CYP2D6—Nilotinib—hematologic cancer	0.00115	0.00391	CbGbCtD
Celecoxib—CYP2D6—Vinorelbine—hematologic cancer	0.00114	0.00388	CbGbCtD
Celecoxib—CYP3A4—Bortezomib—hematologic cancer	0.0011	0.00373	CbGbCtD
Celecoxib—PDPK1—gonad—hematologic cancer	0.00108	0.0527	CbGeAlD
Celecoxib—CYP3A4—Daunorubicin—hematologic cancer	0.00105	0.00357	CbGbCtD
Celecoxib—PDPK1—blood—hematologic cancer	0.000941	0.0459	CbGeAlD
Celecoxib—CYP3A4—Cytarabine—hematologic cancer	0.000925	0.00315	CbGbCtD
Celecoxib—CYP3A4—Teniposide—hematologic cancer	0.000911	0.0031	CbGbCtD
Celecoxib—ALB—Methotrexate—hematologic cancer	0.000847	0.00288	CbGbCtD
Celecoxib—CYP3A4—Ifosfamide—hematologic cancer	0.000841	0.00286	CbGbCtD
Celecoxib—PDPK1—lung—hematologic cancer	0.000825	0.0402	CbGeAlD
Celecoxib—CYP3A4—Imatinib—hematologic cancer	0.000803	0.00274	CbGbCtD
Celecoxib—PDPK1—testis—hematologic cancer	0.000778	0.038	CbGeAlD
Celecoxib—MAPK14—hematopoietic system—hematologic cancer	0.00076	0.037	CbGeAlD
Celecoxib—CYP3A4—Ruxolitinib—hematologic cancer	0.000756	0.00258	CbGbCtD
Celecoxib—CYP3A4—Nilotinib—hematologic cancer	0.00073	0.00249	CbGbCtD
Celecoxib—CYP3A4—Vinorelbine—hematologic cancer	0.000724	0.00246	CbGbCtD
Celecoxib—CYP2C9—Cisplatin—hematologic cancer	0.000703	0.0024	CbGbCtD
Celecoxib—CYP2D6—Vinblastine—hematologic cancer	0.000701	0.00239	CbGbCtD
Celecoxib—CYP3A4—Triamcinolone—hematologic cancer	0.000662	0.00225	CbGbCtD
Celecoxib—CYP3A4—Dasatinib—hematologic cancer	0.000645	0.0022	CbGbCtD
Celecoxib—CYP3A4—Mitoxantrone—hematologic cancer	0.000637	0.00217	CbGbCtD
Celecoxib—CYP2C9—Dexamethasone—hematologic cancer	0.000568	0.00193	CbGbCtD
Celecoxib—CYP3A4—Betamethasone—hematologic cancer	0.000568	0.00193	CbGbCtD
Celecoxib—PDPK1—lymph node—hematologic cancer	0.000564	0.0275	CbGeAlD
Celecoxib—CYP3A4—Prednisolone—hematologic cancer	0.00056	0.00191	CbGbCtD
Celecoxib—CYP3A4—Prednisone—hematologic cancer	0.000529	0.0018	CbGbCtD
Celecoxib—CYP2D6—Dexamethasone—hematologic cancer	0.00052	0.00177	CbGbCtD
Celecoxib—CA5B—hematopoietic system—hematologic cancer	0.000517	0.0252	CbGeAlD
Celecoxib—MAPK14—blood—hematologic cancer	0.000503	0.0245	CbGeAlD
Celecoxib—CYP3A4—Irinotecan—hematologic cancer	0.000502	0.00171	CbGbCtD
Celecoxib—MAPK14—bone marrow—hematologic cancer	0.000487	0.0237	CbGeAlD
Celecoxib—ORM1—hematopoietic system—hematologic cancer	0.000457	0.0223	CbGeAlD
Celecoxib—CYP3A4—Vinblastine—hematologic cancer	0.000446	0.00152	CbGbCtD
Celecoxib—MAPK14—lung—hematologic cancer	0.000441	0.0215	CbGeAlD
Celecoxib—CYP3A4—Vincristine—hematologic cancer	0.000438	0.00149	CbGbCtD
Celecoxib—CYP2D6—Doxorubicin—hematologic cancer	0.000431	0.00147	CbGbCtD
Celecoxib—CA9—testis—hematologic cancer	0.000427	0.0208	CbGeAlD
Celecoxib—MAPK14—testis—hematologic cancer	0.000416	0.0203	CbGeAlD
Celecoxib—CYP3A4—Etoposide—hematologic cancer	0.000402	0.00137	CbGbCtD
Celecoxib—CA5B—gonad—hematologic cancer	0.000393	0.0192	CbGeAlD
Celecoxib—ABCC4—hematopoietic system—hematologic cancer	0.000388	0.0189	CbGeAlD
Celecoxib—CA5B—blood—hematologic cancer	0.000342	0.0167	CbGeAlD
Celecoxib—CA12—lung—hematologic cancer	0.000335	0.0163	CbGeAlD
Celecoxib—CYP3A4—Dexamethasone—hematologic cancer	0.00033	0.00113	CbGbCtD
Celecoxib—ORM1—blood—hematologic cancer	0.000303	0.0148	CbGeAlD
Celecoxib—MAPK14—lymph node—hematologic cancer	0.000302	0.0147	CbGeAlD
Celecoxib—CA5B—lung—hematologic cancer	0.0003	0.0146	CbGeAlD
Celecoxib—CA2—hematopoietic system—hematologic cancer	0.000296	0.0144	CbGeAlD
Celecoxib—ORM1—bone marrow—hematologic cancer	0.000293	0.0143	CbGeAlD
Celecoxib—CA5B—testis—hematologic cancer	0.000283	0.0138	CbGeAlD
Celecoxib—CYP3A4—Doxorubicin—hematologic cancer	0.000274	0.000933	CbGbCtD
Celecoxib—ORM1—lung—hematologic cancer	0.000266	0.013	CbGeAlD
Celecoxib—ABCC4—blood—hematologic cancer	0.000257	0.0125	CbGeAlD
Celecoxib—CYP2C9—hematopoietic system—hematologic cancer	0.00025	0.0122	CbGeAlD
Celecoxib—ABCC4—bone marrow—hematologic cancer	0.000249	0.0121	CbGeAlD
Celecoxib—CA4—blood—hematologic cancer	0.000236	0.0115	CbGeAlD
Celecoxib—CA4—bone marrow—hematologic cancer	0.000229	0.0112	CbGeAlD
Celecoxib—ABCC4—lung—hematologic cancer	0.000225	0.011	CbGeAlD
Celecoxib—ALB—testis—hematologic cancer	0.00022	0.0107	CbGeAlD
Celecoxib—PTGS2—hematopoietic system—hematologic cancer	0.000218	0.0107	CbGeAlD
Celecoxib—ABCC4—testis—hematologic cancer	0.000213	0.0104	CbGeAlD
Celecoxib—CA4—lung—hematologic cancer	0.000207	0.0101	CbGeAlD
Celecoxib—CA5B—lymph node—hematologic cancer	0.000205	0.01	CbGeAlD
Celecoxib—CA2—blood—hematologic cancer	0.000196	0.00956	CbGeAlD
Celecoxib—CA4—testis—hematologic cancer	0.000196	0.00954	CbGeAlD
Celecoxib—CYP3A4—hematopoietic system—hematologic cancer	0.000191	0.00931	CbGeAlD
Celecoxib—CA2—bone marrow—hematologic cancer	0.00019	0.00925	CbGeAlD
Celecoxib—CYP2D6—hematopoietic system—hematologic cancer	0.000188	0.00916	CbGeAlD
Celecoxib—ORM1—lymph node—hematologic cancer	0.000182	0.00886	CbGeAlD
Celecoxib—CA2—lung—hematologic cancer	0.000172	0.00838	CbGeAlD
Celecoxib—CYP2C9—blood—hematologic cancer	0.000166	0.00809	CbGeAlD
Celecoxib—CA2—testis—hematologic cancer	0.000162	0.00791	CbGeAlD
Celecoxib—ALB—lymph node—hematologic cancer	0.000159	0.00777	CbGeAlD
Celecoxib—ABCC4—lymph node—hematologic cancer	0.000154	0.00752	CbGeAlD
Celecoxib—PTGS2—blood—hematologic cancer	0.000145	0.00706	CbGeAlD
Celecoxib—CA4—lymph node—hematologic cancer	0.000142	0.00691	CbGeAlD
Celecoxib—PTGS2—bone marrow—hematologic cancer	0.00014	0.00683	CbGeAlD
Celecoxib—PTGS2—Fluocinonide—Betamethasone—hematologic cancer	0.000138	0.209	CbGdCrCtD
Celecoxib—PTGS2—Fluocinonide—Dexamethasone—hematologic cancer	0.000138	0.209	CbGdCrCtD
Celecoxib—PTGS2—Fluocinonide—Triamcinolone—hematologic cancer	0.000135	0.205	CbGdCrCtD
Celecoxib—PTGS2—lung—hematologic cancer	0.000127	0.00619	CbGeAlD
Celecoxib—CYP3A4—blood—hematologic cancer	0.000126	0.00617	CbGeAlD
Celecoxib—CYP2D6—blood—hematologic cancer	0.000124	0.00607	CbGeAlD
Celecoxib—CA2—lymph node—hematologic cancer	0.000118	0.00573	CbGeAlD
Celecoxib—CYP2D6—testis—hematologic cancer	0.000103	0.00502	CbGeAlD
Celecoxib—PTGS2—lymph node—hematologic cancer	8.68e-05	0.00423	CbGeAlD
Celecoxib—PTGS2—Fluticasone Propionate—Betamethasone—hematologic cancer	8.33e-05	0.126	CbGdCrCtD
Celecoxib—PTGS2—Fluticasone Propionate—Dexamethasone—hematologic cancer	8.33e-05	0.126	CbGdCrCtD
Celecoxib—PTGS2—Fluticasone Propionate—Triamcinolone—hematologic cancer	8.14e-05	0.124	CbGdCrCtD
Celecoxib—Arrhythmia—Epirubicin—hematologic cancer	5.78e-06	5.54e-05	CcSEcCtD
Celecoxib—Nervous system disorder—Prednisone—hematologic cancer	5.76e-06	5.53e-05	CcSEcCtD
Celecoxib—Tachycardia—Prednisone—hematologic cancer	5.73e-06	5.5e-05	CcSEcCtD
Celecoxib—Alopecia—Epirubicin—hematologic cancer	5.71e-06	5.48e-05	CcSEcCtD
Celecoxib—Skin disorder—Prednisone—hematologic cancer	5.7e-06	5.47e-05	CcSEcCtD
Celecoxib—Nausea—Gemcitabine—hematologic cancer	5.7e-06	5.47e-05	CcSEcCtD
Celecoxib—Vomiting—Cisplatin—hematologic cancer	5.69e-06	5.46e-05	CcSEcCtD
Celecoxib—Hyperhidrosis—Prednisone—hematologic cancer	5.68e-06	5.45e-05	CcSEcCtD
Celecoxib—Vision blurred—Methotrexate—hematologic cancer	5.67e-06	5.44e-05	CcSEcCtD
Celecoxib—Mental disorder—Epirubicin—hematologic cancer	5.66e-06	5.44e-05	CcSEcCtD
Celecoxib—Erythema multiforme—Doxorubicin—hematologic cancer	5.66e-06	5.43e-05	CcSEcCtD
Celecoxib—Rash—Cisplatin—hematologic cancer	5.64e-06	5.41e-05	CcSEcCtD
Celecoxib—Dermatitis—Cisplatin—hematologic cancer	5.63e-06	5.41e-05	CcSEcCtD
Celecoxib—Diarrhoea—Etoposide—hematologic cancer	5.61e-06	5.38e-05	CcSEcCtD
Celecoxib—Anorexia—Prednisone—hematologic cancer	5.6e-06	5.37e-05	CcSEcCtD
Celecoxib—Eye disorder—Doxorubicin—hematologic cancer	5.59e-06	5.36e-05	CcSEcCtD
Celecoxib—Tinnitus—Doxorubicin—hematologic cancer	5.58e-06	5.35e-05	CcSEcCtD
Celecoxib—Anaemia—Methotrexate—hematologic cancer	5.56e-06	5.33e-05	CcSEcCtD
Celecoxib—Feeling abnormal—Betamethasone—hematologic cancer	5.56e-06	5.33e-05	CcSEcCtD
Celecoxib—Feeling abnormal—Dexamethasone—hematologic cancer	5.56e-06	5.33e-05	CcSEcCtD
Celecoxib—Flushing—Doxorubicin—hematologic cancer	5.55e-06	5.33e-05	CcSEcCtD
Celecoxib—Cardiac disorder—Doxorubicin—hematologic cancer	5.55e-06	5.33e-05	CcSEcCtD
Celecoxib—Flatulence—Epirubicin—hematologic cancer	5.55e-06	5.32e-05	CcSEcCtD
Celecoxib—Tension—Epirubicin—hematologic cancer	5.52e-06	5.3e-05	CcSEcCtD
Celecoxib—Gastrointestinal pain—Betamethasone—hematologic cancer	5.51e-06	5.29e-05	CcSEcCtD
Celecoxib—Gastrointestinal pain—Dexamethasone—hematologic cancer	5.51e-06	5.29e-05	CcSEcCtD
Celecoxib—Dysgeusia—Epirubicin—hematologic cancer	5.51e-06	5.29e-05	CcSEcCtD
Celecoxib—Hypersensitivity—Triamcinolone—hematologic cancer	5.48e-06	5.25e-05	CcSEcCtD
Celecoxib—Nervousness—Epirubicin—hematologic cancer	5.47e-06	5.25e-05	CcSEcCtD
Celecoxib—Back pain—Epirubicin—hematologic cancer	5.44e-06	5.22e-05	CcSEcCtD
Celecoxib—Angiopathy—Doxorubicin—hematologic cancer	5.43e-06	5.21e-05	CcSEcCtD
Celecoxib—Dizziness—Etoposide—hematologic cancer	5.42e-06	5.2e-05	CcSEcCtD
Celecoxib—Muscle spasms—Epirubicin—hematologic cancer	5.41e-06	5.19e-05	CcSEcCtD
Celecoxib—Immune system disorder—Doxorubicin—hematologic cancer	5.4e-06	5.19e-05	CcSEcCtD
Celecoxib—Vertigo—Methotrexate—hematologic cancer	5.4e-06	5.19e-05	CcSEcCtD
Celecoxib—Mediastinal disorder—Doxorubicin—hematologic cancer	5.39e-06	5.17e-05	CcSEcCtD
Celecoxib—Leukopenia—Methotrexate—hematologic cancer	5.38e-06	5.17e-05	CcSEcCtD
Celecoxib—Urticaria—Betamethasone—hematologic cancer	5.36e-06	5.14e-05	CcSEcCtD
Celecoxib—Urticaria—Dexamethasone—hematologic cancer	5.36e-06	5.14e-05	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Prednisone—hematologic cancer	5.35e-06	5.13e-05	CcSEcCtD
Celecoxib—Dizziness—Prednisolone—hematologic cancer	5.34e-06	5.13e-05	CcSEcCtD
Celecoxib—Arrhythmia—Doxorubicin—hematologic cancer	5.34e-06	5.13e-05	CcSEcCtD
Celecoxib—Asthenia—Triamcinolone—hematologic cancer	5.33e-06	5.12e-05	CcSEcCtD
Celecoxib—Abdominal pain—Dexamethasone—hematologic cancer	5.33e-06	5.12e-05	CcSEcCtD
Celecoxib—Body temperature increased—Betamethasone—hematologic cancer	5.33e-06	5.12e-05	CcSEcCtD
Celecoxib—Abdominal pain—Betamethasone—hematologic cancer	5.33e-06	5.12e-05	CcSEcCtD
Celecoxib—Body temperature increased—Dexamethasone—hematologic cancer	5.33e-06	5.12e-05	CcSEcCtD
Celecoxib—Nausea—Cisplatin—hematologic cancer	5.31e-06	5.1e-05	CcSEcCtD
Celecoxib—Insomnia—Prednisone—hematologic cancer	5.31e-06	5.1e-05	CcSEcCtD
Celecoxib—Vision blurred—Epirubicin—hematologic cancer	5.3e-06	5.09e-05	CcSEcCtD
Celecoxib—Alopecia—Doxorubicin—hematologic cancer	5.29e-06	5.07e-05	CcSEcCtD
Celecoxib—Paraesthesia—Prednisone—hematologic cancer	5.27e-06	5.06e-05	CcSEcCtD
Celecoxib—Pruritus—Triamcinolone—hematologic cancer	5.26e-06	5.05e-05	CcSEcCtD
Celecoxib—Cough—Methotrexate—hematologic cancer	5.25e-06	5.04e-05	CcSEcCtD
Celecoxib—Mental disorder—Doxorubicin—hematologic cancer	5.24e-06	5.03e-05	CcSEcCtD
Celecoxib—Vomiting—Etoposide—hematologic cancer	5.21e-06	5e-05	CcSEcCtD
Celecoxib—Anaemia—Epirubicin—hematologic cancer	5.2e-06	4.99e-05	CcSEcCtD
Celecoxib—Dyspepsia—Prednisone—hematologic cancer	5.17e-06	4.96e-05	CcSEcCtD
Celecoxib—Rash—Etoposide—hematologic cancer	5.17e-06	4.96e-05	CcSEcCtD
Celecoxib—Dermatitis—Etoposide—hematologic cancer	5.16e-06	4.95e-05	CcSEcCtD
Celecoxib—Headache—Etoposide—hematologic cancer	5.13e-06	4.93e-05	CcSEcCtD
Celecoxib—Flatulence—Doxorubicin—hematologic cancer	5.13e-06	4.92e-05	CcSEcCtD
Celecoxib—Arthralgia—Methotrexate—hematologic cancer	5.12e-06	4.91e-05	CcSEcCtD
Celecoxib—Chest pain—Methotrexate—hematologic cancer	5.12e-06	4.91e-05	CcSEcCtD
Celecoxib—Myalgia—Methotrexate—hematologic cancer	5.12e-06	4.91e-05	CcSEcCtD
Celecoxib—Tension—Doxorubicin—hematologic cancer	5.11e-06	4.9e-05	CcSEcCtD
Celecoxib—Decreased appetite—Prednisone—hematologic cancer	5.11e-06	4.9e-05	CcSEcCtD
Celecoxib—Dysgeusia—Doxorubicin—hematologic cancer	5.1e-06	4.89e-05	CcSEcCtD
Celecoxib—Rash—Prednisolone—hematologic cancer	5.1e-06	4.89e-05	CcSEcCtD
Celecoxib—Dermatitis—Prednisolone—hematologic cancer	5.09e-06	4.89e-05	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.08e-06	4.88e-05	CcSEcCtD
Celecoxib—Fatigue—Prednisone—hematologic cancer	5.06e-06	4.86e-05	CcSEcCtD
Celecoxib—Headache—Prednisolone—hematologic cancer	5.06e-06	4.86e-05	CcSEcCtD
Celecoxib—Nervousness—Doxorubicin—hematologic cancer	5.06e-06	4.85e-05	CcSEcCtD
Celecoxib—Vertigo—Epirubicin—hematologic cancer	5.06e-06	4.85e-05	CcSEcCtD
Celecoxib—Syncope—Epirubicin—hematologic cancer	5.05e-06	4.84e-05	CcSEcCtD
Celecoxib—Leukopenia—Epirubicin—hematologic cancer	5.04e-06	4.83e-05	CcSEcCtD
Celecoxib—Back pain—Doxorubicin—hematologic cancer	5.04e-06	4.83e-05	CcSEcCtD
Celecoxib—Constipation—Prednisone—hematologic cancer	5.02e-06	4.82e-05	CcSEcCtD
Celecoxib—Muscle spasms—Doxorubicin—hematologic cancer	5.01e-06	4.8e-05	CcSEcCtD
Celecoxib—Palpitations—Epirubicin—hematologic cancer	4.97e-06	4.77e-05	CcSEcCtD
Celecoxib—Confusional state—Methotrexate—hematologic cancer	4.95e-06	4.75e-05	CcSEcCtD
Celecoxib—Loss of consciousness—Epirubicin—hematologic cancer	4.95e-06	4.75e-05	CcSEcCtD
Celecoxib—Dizziness—Triamcinolone—hematologic cancer	4.91e-06	4.72e-05	CcSEcCtD
Celecoxib—Cough—Epirubicin—hematologic cancer	4.91e-06	4.71e-05	CcSEcCtD
Celecoxib—Anaphylactic shock—Methotrexate—hematologic cancer	4.91e-06	4.71e-05	CcSEcCtD
Celecoxib—Vision blurred—Doxorubicin—hematologic cancer	4.91e-06	4.71e-05	CcSEcCtD
Celecoxib—Infection—Methotrexate—hematologic cancer	4.88e-06	4.68e-05	CcSEcCtD
Celecoxib—Nausea—Etoposide—hematologic cancer	4.87e-06	4.67e-05	CcSEcCtD
Celecoxib—Hypertension—Epirubicin—hematologic cancer	4.86e-06	4.66e-05	CcSEcCtD
Celecoxib—Feeling abnormal—Prednisone—hematologic cancer	4.84e-06	4.64e-05	CcSEcCtD
Celecoxib—Asthenia—Betamethasone—hematologic cancer	4.84e-06	4.64e-05	CcSEcCtD
Celecoxib—Asthenia—Dexamethasone—hematologic cancer	4.84e-06	4.64e-05	CcSEcCtD
Celecoxib—Nervous system disorder—Methotrexate—hematologic cancer	4.81e-06	4.62e-05	CcSEcCtD
Celecoxib—Anaemia—Doxorubicin—hematologic cancer	4.81e-06	4.62e-05	CcSEcCtD
Celecoxib—Thrombocytopenia—Methotrexate—hematologic cancer	4.81e-06	4.61e-05	CcSEcCtD
Celecoxib—Gastrointestinal pain—Prednisone—hematologic cancer	4.8e-06	4.61e-05	CcSEcCtD
Celecoxib—Nausea—Prednisolone—hematologic cancer	4.8e-06	4.61e-05	CcSEcCtD
Celecoxib—Arthralgia—Epirubicin—hematologic cancer	4.79e-06	4.6e-05	CcSEcCtD
Celecoxib—Myalgia—Epirubicin—hematologic cancer	4.79e-06	4.6e-05	CcSEcCtD
Celecoxib—Chest pain—Epirubicin—hematologic cancer	4.79e-06	4.6e-05	CcSEcCtD
Celecoxib—Anxiety—Epirubicin—hematologic cancer	4.78e-06	4.58e-05	CcSEcCtD
Celecoxib—Pruritus—Dexamethasone—hematologic cancer	4.77e-06	4.58e-05	CcSEcCtD
Celecoxib—Pruritus—Betamethasone—hematologic cancer	4.77e-06	4.58e-05	CcSEcCtD
Celecoxib—Skin disorder—Methotrexate—hematologic cancer	4.77e-06	4.58e-05	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.76e-06	4.57e-05	CcSEcCtD
Celecoxib—Hyperhidrosis—Methotrexate—hematologic cancer	4.75e-06	4.55e-05	CcSEcCtD
Celecoxib—Vomiting—Triamcinolone—hematologic cancer	4.73e-06	4.53e-05	CcSEcCtD
Celecoxib—Rash—Triamcinolone—hematologic cancer	4.69e-06	4.5e-05	CcSEcCtD
Celecoxib—Dry mouth—Epirubicin—hematologic cancer	4.69e-06	4.5e-05	CcSEcCtD
Celecoxib—Dermatitis—Triamcinolone—hematologic cancer	4.68e-06	4.49e-05	CcSEcCtD
Celecoxib—Vertigo—Doxorubicin—hematologic cancer	4.68e-06	4.49e-05	CcSEcCtD
Celecoxib—Anorexia—Methotrexate—hematologic cancer	4.68e-06	4.49e-05	CcSEcCtD
Celecoxib—Syncope—Doxorubicin—hematologic cancer	4.67e-06	4.48e-05	CcSEcCtD
Celecoxib—Urticaria—Prednisone—hematologic cancer	4.67e-06	4.48e-05	CcSEcCtD
Celecoxib—Leukopenia—Doxorubicin—hematologic cancer	4.66e-06	4.47e-05	CcSEcCtD
Celecoxib—Headache—Triamcinolone—hematologic cancer	4.66e-06	4.47e-05	CcSEcCtD
Celecoxib—Abdominal pain—Prednisone—hematologic cancer	4.64e-06	4.46e-05	CcSEcCtD
Celecoxib—Body temperature increased—Prednisone—hematologic cancer	4.64e-06	4.46e-05	CcSEcCtD
Celecoxib—Confusional state—Epirubicin—hematologic cancer	4.63e-06	4.44e-05	CcSEcCtD
Celecoxib—Diarrhoea—Dexamethasone—hematologic cancer	4.61e-06	4.43e-05	CcSEcCtD
Celecoxib—Diarrhoea—Betamethasone—hematologic cancer	4.61e-06	4.43e-05	CcSEcCtD
Celecoxib—Palpitations—Doxorubicin—hematologic cancer	4.6e-06	4.42e-05	CcSEcCtD
Celecoxib—Oedema—Epirubicin—hematologic cancer	4.59e-06	4.41e-05	CcSEcCtD
Celecoxib—Anaphylactic shock—Epirubicin—hematologic cancer	4.59e-06	4.41e-05	CcSEcCtD
Celecoxib—Loss of consciousness—Doxorubicin—hematologic cancer	4.58e-06	4.39e-05	CcSEcCtD
Celecoxib—Infection—Epirubicin—hematologic cancer	4.56e-06	4.38e-05	CcSEcCtD
Celecoxib—Cough—Doxorubicin—hematologic cancer	4.54e-06	4.36e-05	CcSEcCtD
Celecoxib—Shock—Epirubicin—hematologic cancer	4.52e-06	4.34e-05	CcSEcCtD
Celecoxib—Nervous system disorder—Epirubicin—hematologic cancer	4.5e-06	4.32e-05	CcSEcCtD
Celecoxib—Thrombocytopenia—Epirubicin—hematologic cancer	4.5e-06	4.32e-05	CcSEcCtD
Celecoxib—Hypertension—Doxorubicin—hematologic cancer	4.5e-06	4.31e-05	CcSEcCtD
Celecoxib—Tachycardia—Epirubicin—hematologic cancer	4.48e-06	4.3e-05	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.47e-06	4.29e-05	CcSEcCtD
Celecoxib—Skin disorder—Epirubicin—hematologic cancer	4.46e-06	4.28e-05	CcSEcCtD
Celecoxib—Dizziness—Dexamethasone—hematologic cancer	4.46e-06	4.28e-05	CcSEcCtD
Celecoxib—Dizziness—Betamethasone—hematologic cancer	4.46e-06	4.28e-05	CcSEcCtD
Celecoxib—Hyperhidrosis—Epirubicin—hematologic cancer	4.44e-06	4.26e-05	CcSEcCtD
Celecoxib—Insomnia—Methotrexate—hematologic cancer	4.44e-06	4.26e-05	CcSEcCtD
Celecoxib—Arthralgia—Doxorubicin—hematologic cancer	4.43e-06	4.25e-05	CcSEcCtD
Celecoxib—Myalgia—Doxorubicin—hematologic cancer	4.43e-06	4.25e-05	CcSEcCtD
Celecoxib—Chest pain—Doxorubicin—hematologic cancer	4.43e-06	4.25e-05	CcSEcCtD
Celecoxib—Anxiety—Doxorubicin—hematologic cancer	4.42e-06	4.24e-05	CcSEcCtD
Celecoxib—Nausea—Triamcinolone—hematologic cancer	4.41e-06	4.24e-05	CcSEcCtD
Celecoxib—Paraesthesia—Methotrexate—hematologic cancer	4.41e-06	4.23e-05	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.4e-06	4.23e-05	CcSEcCtD
Celecoxib—Anorexia—Epirubicin—hematologic cancer	4.38e-06	4.2e-05	CcSEcCtD
Celecoxib—Dyspnoea—Methotrexate—hematologic cancer	4.38e-06	4.2e-05	CcSEcCtD
Celecoxib—Somnolence—Methotrexate—hematologic cancer	4.36e-06	4.19e-05	CcSEcCtD
Celecoxib—Dry mouth—Doxorubicin—hematologic cancer	4.34e-06	4.16e-05	CcSEcCtD
Celecoxib—Hypersensitivity—Prednisone—hematologic cancer	4.33e-06	4.15e-05	CcSEcCtD
Celecoxib—Dyspepsia—Methotrexate—hematologic cancer	4.32e-06	4.15e-05	CcSEcCtD
Celecoxib—Vomiting—Betamethasone—hematologic cancer	4.29e-06	4.11e-05	CcSEcCtD
Celecoxib—Vomiting—Dexamethasone—hematologic cancer	4.29e-06	4.11e-05	CcSEcCtD
Celecoxib—Confusional state—Doxorubicin—hematologic cancer	4.29e-06	4.11e-05	CcSEcCtD
Celecoxib—Decreased appetite—Methotrexate—hematologic cancer	4.27e-06	4.09e-05	CcSEcCtD
Celecoxib—Rash—Dexamethasone—hematologic cancer	4.25e-06	4.08e-05	CcSEcCtD
Celecoxib—Rash—Betamethasone—hematologic cancer	4.25e-06	4.08e-05	CcSEcCtD
Celecoxib—Anaphylactic shock—Doxorubicin—hematologic cancer	4.25e-06	4.08e-05	CcSEcCtD
Celecoxib—Oedema—Doxorubicin—hematologic cancer	4.25e-06	4.08e-05	CcSEcCtD
Celecoxib—Dermatitis—Dexamethasone—hematologic cancer	4.25e-06	4.08e-05	CcSEcCtD
Celecoxib—Dermatitis—Betamethasone—hematologic cancer	4.25e-06	4.08e-05	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.24e-06	4.07e-05	CcSEcCtD
Celecoxib—Fatigue—Methotrexate—hematologic cancer	4.23e-06	4.06e-05	CcSEcCtD
Celecoxib—Headache—Dexamethasone—hematologic cancer	4.22e-06	4.05e-05	CcSEcCtD
Celecoxib—Headache—Betamethasone—hematologic cancer	4.22e-06	4.05e-05	CcSEcCtD
Celecoxib—Infection—Doxorubicin—hematologic cancer	4.22e-06	4.05e-05	CcSEcCtD
Celecoxib—Asthenia—Prednisone—hematologic cancer	4.21e-06	4.04e-05	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.18e-06	4.02e-05	CcSEcCtD
Celecoxib—Shock—Doxorubicin—hematologic cancer	4.18e-06	4.01e-05	CcSEcCtD
Celecoxib—Nervous system disorder—Doxorubicin—hematologic cancer	4.17e-06	4e-05	CcSEcCtD
Celecoxib—Thrombocytopenia—Doxorubicin—hematologic cancer	4.16e-06	3.99e-05	CcSEcCtD
Celecoxib—Pruritus—Prednisone—hematologic cancer	4.16e-06	3.99e-05	CcSEcCtD
Celecoxib—Insomnia—Epirubicin—hematologic cancer	4.15e-06	3.99e-05	CcSEcCtD
Celecoxib—Tachycardia—Doxorubicin—hematologic cancer	4.15e-06	3.98e-05	CcSEcCtD
Celecoxib—Skin disorder—Doxorubicin—hematologic cancer	4.13e-06	3.96e-05	CcSEcCtD
Celecoxib—Paraesthesia—Epirubicin—hematologic cancer	4.12e-06	3.96e-05	CcSEcCtD
Celecoxib—Hyperhidrosis—Doxorubicin—hematologic cancer	4.11e-06	3.94e-05	CcSEcCtD
Celecoxib—Dyspnoea—Epirubicin—hematologic cancer	4.1e-06	3.93e-05	CcSEcCtD
Celecoxib—Somnolence—Epirubicin—hematologic cancer	4.08e-06	3.92e-05	CcSEcCtD
Celecoxib—Anorexia—Doxorubicin—hematologic cancer	4.05e-06	3.89e-05	CcSEcCtD
Celecoxib—Feeling abnormal—Methotrexate—hematologic cancer	4.04e-06	3.88e-05	CcSEcCtD
Celecoxib—Dyspepsia—Epirubicin—hematologic cancer	4.04e-06	3.88e-05	CcSEcCtD
Celecoxib—Diarrhoea—Prednisone—hematologic cancer	4.02e-06	3.86e-05	CcSEcCtD
Celecoxib—Gastrointestinal pain—Methotrexate—hematologic cancer	4.01e-06	3.85e-05	CcSEcCtD
Celecoxib—Nausea—Dexamethasone—hematologic cancer	4.01e-06	3.84e-05	CcSEcCtD
Celecoxib—Nausea—Betamethasone—hematologic cancer	4.01e-06	3.84e-05	CcSEcCtD
Celecoxib—Decreased appetite—Epirubicin—hematologic cancer	3.99e-06	3.83e-05	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.97e-06	3.81e-05	CcSEcCtD
Celecoxib—Fatigue—Epirubicin—hematologic cancer	3.96e-06	3.8e-05	CcSEcCtD
Celecoxib—Constipation—Epirubicin—hematologic cancer	3.93e-06	3.77e-05	CcSEcCtD
Celecoxib—Urticaria—Methotrexate—hematologic cancer	3.9e-06	3.74e-05	CcSEcCtD
Celecoxib—Dizziness—Prednisone—hematologic cancer	3.88e-06	3.73e-05	CcSEcCtD
Celecoxib—Body temperature increased—Methotrexate—hematologic cancer	3.88e-06	3.72e-05	CcSEcCtD
Celecoxib—Abdominal pain—Methotrexate—hematologic cancer	3.88e-06	3.72e-05	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.87e-06	3.72e-05	CcSEcCtD
Celecoxib—Insomnia—Doxorubicin—hematologic cancer	3.84e-06	3.69e-05	CcSEcCtD
Celecoxib—Paraesthesia—Doxorubicin—hematologic cancer	3.82e-06	3.66e-05	CcSEcCtD
Celecoxib—Dyspnoea—Doxorubicin—hematologic cancer	3.79e-06	3.64e-05	CcSEcCtD
Celecoxib—Feeling abnormal—Epirubicin—hematologic cancer	3.79e-06	3.63e-05	CcSEcCtD
Celecoxib—Somnolence—Doxorubicin—hematologic cancer	3.78e-06	3.63e-05	CcSEcCtD
Celecoxib—Gastrointestinal pain—Epirubicin—hematologic cancer	3.76e-06	3.6e-05	CcSEcCtD
Celecoxib—Dyspepsia—Doxorubicin—hematologic cancer	3.74e-06	3.59e-05	CcSEcCtD
Celecoxib—Vomiting—Prednisone—hematologic cancer	3.73e-06	3.58e-05	CcSEcCtD
Celecoxib—Rash—Prednisone—hematologic cancer	3.7e-06	3.55e-05	CcSEcCtD
Celecoxib—Dermatitis—Prednisone—hematologic cancer	3.7e-06	3.55e-05	CcSEcCtD
Celecoxib—Decreased appetite—Doxorubicin—hematologic cancer	3.69e-06	3.55e-05	CcSEcCtD
Celecoxib—Headache—Prednisone—hematologic cancer	3.68e-06	3.53e-05	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.67e-06	3.52e-05	CcSEcCtD
Celecoxib—Fatigue—Doxorubicin—hematologic cancer	3.66e-06	3.52e-05	CcSEcCtD
Celecoxib—Urticaria—Epirubicin—hematologic cancer	3.65e-06	3.5e-05	CcSEcCtD
Celecoxib—Constipation—Doxorubicin—hematologic cancer	3.63e-06	3.49e-05	CcSEcCtD
Celecoxib—Body temperature increased—Epirubicin—hematologic cancer	3.63e-06	3.48e-05	CcSEcCtD
Celecoxib—Abdominal pain—Epirubicin—hematologic cancer	3.63e-06	3.48e-05	CcSEcCtD
Celecoxib—Hypersensitivity—Methotrexate—hematologic cancer	3.62e-06	3.47e-05	CcSEcCtD
Celecoxib—Asthenia—Methotrexate—hematologic cancer	3.52e-06	3.38e-05	CcSEcCtD
Celecoxib—Feeling abnormal—Doxorubicin—hematologic cancer	3.5e-06	3.36e-05	CcSEcCtD
Celecoxib—Nausea—Prednisone—hematologic cancer	3.49e-06	3.35e-05	CcSEcCtD
Celecoxib—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.48e-06	3.34e-05	CcSEcCtD
Celecoxib—Pruritus—Methotrexate—hematologic cancer	3.47e-06	3.33e-05	CcSEcCtD
Celecoxib—Hypersensitivity—Epirubicin—hematologic cancer	3.38e-06	3.25e-05	CcSEcCtD
Celecoxib—Urticaria—Doxorubicin—hematologic cancer	3.38e-06	3.24e-05	CcSEcCtD
Celecoxib—Abdominal pain—Doxorubicin—hematologic cancer	3.36e-06	3.22e-05	CcSEcCtD
Celecoxib—Body temperature increased—Doxorubicin—hematologic cancer	3.36e-06	3.22e-05	CcSEcCtD
Celecoxib—Diarrhoea—Methotrexate—hematologic cancer	3.36e-06	3.22e-05	CcSEcCtD
Celecoxib—Asthenia—Epirubicin—hematologic cancer	3.3e-06	3.16e-05	CcSEcCtD
Celecoxib—Pruritus—Epirubicin—hematologic cancer	3.25e-06	3.12e-05	CcSEcCtD
Celecoxib—Dizziness—Methotrexate—hematologic cancer	3.25e-06	3.11e-05	CcSEcCtD
Celecoxib—Diarrhoea—Epirubicin—hematologic cancer	3.14e-06	3.02e-05	CcSEcCtD
Celecoxib—Hypersensitivity—Doxorubicin—hematologic cancer	3.13e-06	3e-05	CcSEcCtD
Celecoxib—Vomiting—Methotrexate—hematologic cancer	3.12e-06	2.99e-05	CcSEcCtD
Celecoxib—Rash—Methotrexate—hematologic cancer	3.09e-06	2.97e-05	CcSEcCtD
Celecoxib—Dermatitis—Methotrexate—hematologic cancer	3.09e-06	2.97e-05	CcSEcCtD
Celecoxib—Headache—Methotrexate—hematologic cancer	3.07e-06	2.95e-05	CcSEcCtD
Celecoxib—Asthenia—Doxorubicin—hematologic cancer	3.05e-06	2.93e-05	CcSEcCtD
Celecoxib—Dizziness—Epirubicin—hematologic cancer	3.04e-06	2.91e-05	CcSEcCtD
Celecoxib—Pruritus—Doxorubicin—hematologic cancer	3.01e-06	2.89e-05	CcSEcCtD
Celecoxib—Vomiting—Epirubicin—hematologic cancer	2.92e-06	2.8e-05	CcSEcCtD
Celecoxib—Nausea—Methotrexate—hematologic cancer	2.92e-06	2.8e-05	CcSEcCtD
Celecoxib—Diarrhoea—Doxorubicin—hematologic cancer	2.91e-06	2.79e-05	CcSEcCtD
Celecoxib—Rash—Epirubicin—hematologic cancer	2.9e-06	2.78e-05	CcSEcCtD
Celecoxib—Dermatitis—Epirubicin—hematologic cancer	2.89e-06	2.78e-05	CcSEcCtD
Celecoxib—Headache—Epirubicin—hematologic cancer	2.88e-06	2.76e-05	CcSEcCtD
Celecoxib—Dizziness—Doxorubicin—hematologic cancer	2.81e-06	2.7e-05	CcSEcCtD
Celecoxib—Nausea—Epirubicin—hematologic cancer	2.73e-06	2.62e-05	CcSEcCtD
Celecoxib—Vomiting—Doxorubicin—hematologic cancer	2.7e-06	2.59e-05	CcSEcCtD
Celecoxib—Rash—Doxorubicin—hematologic cancer	2.68e-06	2.57e-05	CcSEcCtD
Celecoxib—Dermatitis—Doxorubicin—hematologic cancer	2.68e-06	2.57e-05	CcSEcCtD
Celecoxib—Headache—Doxorubicin—hematologic cancer	2.66e-06	2.56e-05	CcSEcCtD
Celecoxib—Nausea—Doxorubicin—hematologic cancer	2.52e-06	2.42e-05	CcSEcCtD
Celecoxib—ALB—Hemostasis—IL2—hematologic cancer	7.4e-07	9.78e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—HMMR—hematologic cancer	7.38e-07	9.76e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—IDH2—hematologic cancer	7.38e-07	9.76e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GSTT1—hematologic cancer	7.38e-07	9.75e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	7.33e-07	9.7e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ABCB1—hematologic cancer	7.31e-07	9.66e-06	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MYC—hematologic cancer	7.3e-07	9.65e-06	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—JUN—hematologic cancer	7.3e-07	9.65e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—ESR1—hematologic cancer	7.29e-07	9.64e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PDGFB—hematologic cancer	7.29e-07	9.63e-06	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TGFB1—hematologic cancer	7.28e-07	9.63e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—SDC1—hematologic cancer	7.27e-07	9.62e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	7.26e-07	9.6e-06	CbGpPWpGaD
Celecoxib—PDPK1—Disease—AKT1—hematologic cancer	7.23e-07	9.56e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—SDC1—hematologic cancer	7.21e-07	9.53e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FN1—hematologic cancer	7.2e-07	9.53e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TSC2—hematologic cancer	7.12e-07	9.42e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NFKBIA—hematologic cancer	7.12e-07	9.41e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—BAD—hematologic cancer	7.12e-07	9.41e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—NCOR1—hematologic cancer	7.09e-07	9.38e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GSTM1—hematologic cancer	7.09e-07	9.38e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CYCS—hematologic cancer	7.09e-07	9.37e-06	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CDKN1A—hematologic cancer	7.08e-07	9.36e-06	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PTEN—hematologic cancer	7.06e-07	9.34e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NOTCH1—hematologic cancer	7.05e-07	9.32e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—HSP90AA1—hematologic cancer	7.04e-07	9.31e-06	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—AKT1—hematologic cancer	6.99e-07	9.24e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ARNTL—hematologic cancer	6.94e-07	9.17e-06	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—MAPK8—hematologic cancer	6.91e-07	9.13e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CD80—hematologic cancer	6.91e-07	9.13e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KIT—hematologic cancer	6.89e-07	9.12e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CG—hematologic cancer	6.89e-07	9.12e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	6.89e-07	9.11e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—FGFR3—hematologic cancer	6.85e-07	9.06e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	6.8e-07	8.99e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTPN11—hematologic cancer	6.77e-07	8.96e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CA9—hematologic cancer	6.75e-07	8.92e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ACP5—hematologic cancer	6.75e-07	8.92e-06	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—KRAS—hematologic cancer	6.75e-07	8.92e-06	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—EP300—hematologic cancer	6.73e-07	8.9e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NCOR2—hematologic cancer	6.66e-07	8.81e-06	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—EP300—hematologic cancer	6.64e-07	8.78e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CREB1—hematologic cancer	6.56e-07	8.68e-06	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—SRC—hematologic cancer	6.55e-07	8.66e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	6.5e-07	8.6e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—BAD—hematologic cancer	6.49e-07	8.59e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—BRAF—hematologic cancer	6.48e-07	8.57e-06	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—SRC—hematologic cancer	6.45e-07	8.53e-06	CbGpPWpGaD
Celecoxib—CA4—Metabolism—AKT1—hematologic cancer	6.45e-07	8.53e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NOTCH1—hematologic cancer	6.43e-07	8.5e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCL2—hematologic cancer	6.42e-07	8.49e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL6R—hematologic cancer	6.4e-07	8.47e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CREBBP—hematologic cancer	6.39e-07	8.45e-06	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PIK3CA—hematologic cancer	6.38e-07	8.44e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—IDH1—hematologic cancer	6.34e-07	8.39e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	6.34e-07	8.38e-06	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—STAT3—hematologic cancer	6.31e-07	8.35e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CD80—hematologic cancer	6.3e-07	8.33e-06	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—NRAS—hematologic cancer	6.3e-07	8.33e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KIT—hematologic cancer	6.29e-07	8.32e-06	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—VEGFA—hematologic cancer	6.29e-07	8.31e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTO1—hematologic cancer	6.27e-07	8.29e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—TXN—hematologic cancer	6.27e-07	8.29e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ABCC3—hematologic cancer	6.27e-07	8.29e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—MTHFR—hematologic cancer	6.27e-07	8.29e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GSTP1—hematologic cancer	6.25e-07	8.26e-06	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—NRAS—hematologic cancer	6.21e-07	8.21e-06	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PIK3CA—hematologic cancer	6.2e-07	8.19e-06	CbGpPWpGaD
Celecoxib—CA2—Metabolism—AKT1—hematologic cancer	6.19e-07	8.18e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—NQO1—hematologic cancer	6.18e-07	8.18e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CD44—hematologic cancer	6.18e-07	8.18e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PTPN11—hematologic cancer	6.18e-07	8.17e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SPHK1—hematologic cancer	6.14e-07	8.12e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CD44—hematologic cancer	6.13e-07	8.1e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—NQO1—hematologic cancer	6.13e-07	8.1e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MAP2K1—hematologic cancer	6.1e-07	8.07e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CD—hematologic cancer	6.06e-07	8.01e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	6.04e-07	7.99e-06	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—MAPK3—hematologic cancer	6.03e-07	7.98e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	6e-07	7.94e-06	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—MAPK3—hematologic cancer	6e-07	7.93e-06	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TP53—hematologic cancer	6e-07	7.93e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CREB1—hematologic cancer	5.99e-07	7.92e-06	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—MAPK3—hematologic cancer	5.95e-07	7.86e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—BRAF—hematologic cancer	5.91e-07	7.82e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ABCB1—hematologic cancer	5.91e-07	7.82e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—UGT1A1—hematologic cancer	5.9e-07	7.8e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYCS—hematologic cancer	5.85e-07	7.74e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—IL6R—hematologic cancer	5.84e-07	7.72e-06	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—MYC—hematologic cancer	5.83e-07	7.72e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CREBBP—hematologic cancer	5.83e-07	7.71e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	5.81e-07	7.69e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FGF2—hematologic cancer	5.8e-07	7.67e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYCS—hematologic cancer	5.8e-07	7.67e-06	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TGFB1—hematologic cancer	5.77e-07	7.63e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	5.76e-07	7.62e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—NCOR1—hematologic cancer	5.74e-07	7.59e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GSTM1—hematologic cancer	5.74e-07	7.59e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SLC22A1—hematologic cancer	5.74e-07	7.59e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CRABP1—hematologic cancer	5.74e-07	7.59e-06	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—HRAS—hematologic cancer	5.73e-07	7.58e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3R1—hematologic cancer	5.72e-07	7.57e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ALOX5—hematologic cancer	5.59e-07	7.39e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MAP2K1—hematologic cancer	5.57e-07	7.36e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—JAK2—hematologic cancer	5.56e-07	7.36e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CD—hematologic cancer	5.53e-07	7.31e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.53e-07	7.31e-06	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IL6—hematologic cancer	5.49e-07	7.26e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MDM2—hematologic cancer	5.43e-07	7.18e-06	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—KRAS—hematologic cancer	5.42e-07	7.17e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NUP98—hematologic cancer	5.42e-07	7.16e-06	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—KRAS—hematologic cancer	5.34e-07	7.07e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—FGF2—hematologic cancer	5.29e-07	7e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MTOR—hematologic cancer	5.28e-07	6.99e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CB—hematologic cancer	5.28e-07	6.99e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CG—hematologic cancer	5.27e-07	6.97e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ADCY7—hematologic cancer	5.26e-07	6.95e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NCOA3—hematologic cancer	5.26e-07	6.95e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3R1—hematologic cancer	5.22e-07	6.9e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NUP214—hematologic cancer	5.22e-07	6.9e-06	CbGpPWpGaD
Celecoxib—CA9—Metabolism—AKT1—hematologic cancer	5.21e-07	6.9e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.19e-07	6.86e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GSTP1—hematologic cancer	5.16e-07	6.82e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—MTR—hematologic cancer	5.11e-07	6.76e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ABCG2—hematologic cancer	5.11e-07	6.76e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GSTP1—hematologic cancer	5.11e-07	6.76e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—JAK2—hematologic cancer	5.07e-07	6.71e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—MTHFR—hematologic cancer	5.07e-07	6.71e-06	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—AKT1—hematologic cancer	5.06e-07	6.69e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ENO2—hematologic cancer	5.02e-07	6.63e-06	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PIK3CA—hematologic cancer	4.98e-07	6.59e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CDKN1B—hematologic cancer	4.96e-07	6.56e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MDM2—hematologic cancer	4.95e-07	6.55e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.95e-07	6.54e-06	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CA—hematologic cancer	4.91e-07	6.49e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CREBBP—hematologic cancer	4.88e-07	6.46e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ABCB1—hematologic cancer	4.88e-07	6.45e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTT1—hematologic cancer	4.86e-07	6.43e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CASP3—hematologic cancer	4.86e-07	6.43e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL2—hematologic cancer	4.85e-07	6.42e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ABCB1—hematologic cancer	4.84e-07	6.4e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CB—hematologic cancer	4.82e-07	6.37e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MTOR—hematologic cancer	4.82e-07	6.37e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CD4—hematologic cancer	4.81e-07	6.36e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SDC1—hematologic cancer	4.75e-07	6.29e-06	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TP53—hematologic cancer	4.75e-07	6.28e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GSTM1—hematologic cancer	4.74e-07	6.27e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—NCOR1—hematologic cancer	4.74e-07	6.27e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCND1—hematologic cancer	4.73e-07	6.25e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—JUN—hematologic cancer	4.72e-07	6.24e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—NCOR1—hematologic cancer	4.7e-07	6.21e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GSTM1—hematologic cancer	4.7e-07	6.21e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CD—hematologic cancer	4.63e-07	6.12e-06	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HRAS—hematologic cancer	4.61e-07	6.09e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CDKN1A—hematologic cancer	4.58e-07	6.05e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ALB—hematologic cancer	4.57e-07	6.04e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTEN—hematologic cancer	4.57e-07	6.04e-06	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—HRAS—hematologic cancer	4.54e-07	6.01e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CDKN1B—hematologic cancer	4.52e-07	5.98e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.47e-07	5.91e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MAPK8—hematologic cancer	4.47e-07	5.91e-06	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL6—hematologic cancer	4.41e-07	5.83e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3R1—hematologic cancer	4.37e-07	5.78e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—EP300—hematologic cancer	4.35e-07	5.76e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CG—hematologic cancer	4.26e-07	5.64e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—SRC—hematologic cancer	4.23e-07	5.6e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—MTHFR—hematologic cancer	4.19e-07	5.54e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CDKN1A—hematologic cancer	4.17e-07	5.52e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PTEN—hematologic cancer	4.16e-07	5.51e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—MTHFR—hematologic cancer	4.15e-07	5.49e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—VEGFA—hematologic cancer	4.12e-07	5.45e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—STAT3—hematologic cancer	4.08e-07	5.4e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NRAS—hematologic cancer	4.07e-07	5.39e-06	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—AKT1—hematologic cancer	4.07e-07	5.38e-06	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—AKT1—hematologic cancer	4.05e-07	5.35e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CD44—hematologic cancer	4.04e-07	5.35e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NQO1—hematologic cancer	4.04e-07	5.35e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CB—hematologic cancer	4.04e-07	5.34e-06	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—AKT1—hematologic cancer	4.01e-07	5.3e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—EP300—hematologic cancer	3.97e-07	5.25e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CREBBP—hematologic cancer	3.95e-07	5.22e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MAPK3—hematologic cancer	3.9e-07	5.16e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—SRC—hematologic cancer	3.86e-07	5.11e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYCS—hematologic cancer	3.83e-07	5.06e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.8e-07	5.03e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MYC—hematologic cancer	3.79e-07	5.02e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TGFB1—hematologic cancer	3.78e-07	5e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CD—hematologic cancer	3.75e-07	4.95e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—STAT3—hematologic cancer	3.72e-07	4.93e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NRAS—hematologic cancer	3.72e-07	4.91e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.66e-07	4.84e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MAPK3—hematologic cancer	3.56e-07	4.71e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3R1—hematologic cancer	3.54e-07	4.68e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CG—hematologic cancer	3.52e-07	4.65e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KRAS—hematologic cancer	3.51e-07	4.64e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CG—hematologic cancer	3.49e-07	4.61e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PTEN—hematologic cancer	3.49e-07	4.61e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MYC—hematologic cancer	3.46e-07	4.58e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TGFB1—hematologic cancer	3.45e-07	4.57e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.37e-07	4.46e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—EP300—hematologic cancer	3.33e-07	4.4e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CB—hematologic cancer	3.27e-07	4.32e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CREBBP—hematologic cancer	3.26e-07	4.31e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CREBBP—hematologic cancer	3.23e-07	4.28e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CA—hematologic cancer	3.22e-07	4.26e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KRAS—hematologic cancer	3.2e-07	4.23e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.19e-07	4.22e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TP53—hematologic cancer	3.12e-07	4.12e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.1e-07	4.1e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.1e-07	4.1e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CD—hematologic cancer	3.09e-07	4.09e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CD—hematologic cancer	3.07e-07	4.05e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ALB—hematologic cancer	3.05e-07	4.04e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ALB—hematologic cancer	3.03e-07	4e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HRAS—hematologic cancer	2.98e-07	3.94e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CA—hematologic cancer	2.94e-07	3.88e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.92e-07	3.86e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3R1—hematologic cancer	2.9e-07	3.83e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL6—hematologic cancer	2.85e-07	3.77e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTEN—hematologic cancer	2.82e-07	3.73e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.74e-07	3.62e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HRAS—hematologic cancer	2.72e-07	3.59e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.7e-07	3.57e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—EP300—hematologic cancer	2.69e-07	3.56e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CB—hematologic cancer	2.67e-07	3.53e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—AKT1—hematologic cancer	2.63e-07	3.48e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—IL6—hematologic cancer	2.6e-07	3.44e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CA—hematologic cancer	2.46e-07	3.25e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—AKT1—hematologic cancer	2.4e-07	3.17e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTEN—hematologic cancer	2.33e-07	3.08e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTEN—hematologic cancer	2.31e-07	3.05e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.3e-07	3.04e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—EP300—hematologic cancer	2.22e-07	2.94e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—EP300—hematologic cancer	2.2e-07	2.91e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.13e-07	2.82e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.02e-07	2.67e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—AKT1—hematologic cancer	2.01e-07	2.66e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ALB—hematologic cancer	2e-07	2.64e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CA—hematologic cancer	1.99e-07	2.63e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.91e-07	2.53e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.76e-07	2.33e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.64e-07	2.17e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CA—hematologic cancer	1.63e-07	2.15e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—AKT1—hematologic cancer	1.63e-07	2.15e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTEN—hematologic cancer	1.52e-07	2.01e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—EP300—hematologic cancer	1.45e-07	1.92e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—AKT1—hematologic cancer	1.34e-07	1.78e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—AKT1—hematologic cancer	1.33e-07	1.76e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.07e-07	1.42e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—AKT1—hematologic cancer	8.78e-08	1.16e-06	CbGpPWpGaD
